Pharosyn has raised $3.0M in seed funding, a bet that biopharma’s competitive intelligence problem is too sprawling for manual tracking. The round was backed by Moonfire Ventures, Entrepreneurs First, Transpose Platform, and General Advance.
The London-based startup has built an AI platform that continuously scans thousands of clinical, regulatory, and commercial data sources, then auto-generates strategic reports tailored to a company’s specific pipeline. For pharma and biotech teams, that means less time sifting through trial updates or regulatory filings and more clarity on what rivals are actually doing-whether it’s flagging an event worth prioritizing or refreshing the competitive landscape on a regular cadence. The funding arrives as drug developers face mounting pressure to move faster, and Pharosyn is positioning itself as the always-on analyst they didn’t have to hire.
